Aim and Scope: Substantial morbidity and mortality is caused by respiratory complications in 40–60% of patients after HSCT. Bronchiolitis obliterans syndrome (BOS) is reported in 2–13% of patients, occurring within 6–12 months post transplant. The LEWP launched a retrospective survey in 2003 to document the incidence, current practice for the diagnosis, clinical work-up and treatment of BOS after allogeneic HSCT.

Patients&Method: Between 2003 – 2005, 31 centers reported 226 patients with BOS. Adjusted BOS criteria were accepted (normal spirometry pretransplant, respiratory symptoms in the absence of an infection and combination of 3/4 items at onset: FEV1 <80% predicted/measured; FEV1/FVC <80% and MMFR <50% predicted/measured and residual volume >120%; HR CAT scan of the thorax. FOB and BAL were used in 60% of centers, but open lung bx.was not recommended by 75%.

Results: The median age of the patients was 30.9 years (1–62) and 19% was pediatric. The donors were 64.6% siblings. HSCT indication was hematological malignancy in 92.3% (37% AL, 21% CL). The graft source was BM in 60% and PBSC in 39%. The preparative regimen was myeloablation in 85.8%. The majority of the patients had antecedent GVHD (acute 66%, chronic 89%). The median interval from transplant to onset of BOS was 11.7 mo.s (1–260). Two third of the patients are still alive (22% in remission and 70% still receiving therapy). Median survival is 39.5 mo.s (1–277). The main reasons for high mortality rate are BOS (69%), relapse (15%) and GVHD (14%). The results of the univariate analysis on KM curves are summarized in Table 1.

Conclusion: Univariate data showed a negative impact of male gender, early onset (<11.7 mo.s) and MUD transplants. BOS is still an important cause of non-relapse late morbidity and mortality. Diagnosis and treatment are difficult and heterogeneous. The final analysis with multivariate methods should validate current results.

Variables tested in univariate analyses

VariablesMed. OS, months (95% CI)P
NR: not reached 
Sibling/MUD NR 75.9 (28.1–123.6) 043 
Male/Female 72.5 (47.6–97.4) NR 0.038 
Onset: Early/Late 59 (33.3–84.8) NR 0.00001 
Ablative/Non Ablative 102.8 (67.7–137.9) NR 0.191 
VariablesMed. OS, months (95% CI)P
NR: not reached 
Sibling/MUD NR 75.9 (28.1–123.6) 043 
Male/Female 72.5 (47.6–97.4) NR 0.038 
Onset: Early/Late 59 (33.3–84.8) NR 0.00001 
Ablative/Non Ablative 102.8 (67.7–137.9) NR 0.191 

Disclosure: No relevant conflicts of interest to declare.

Author notes

*

Corresponding author

Sign in via your Institution